Clinical Trials Logo

Clinical Trial Summary

A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various solid tumor types. The study seeks to determine a safe dose of the combination of study drugs and then examine this dose in larger groups of patients of specific tumor types to evaluate its anti-tumor efficacy. Treatment will continue in patients who respond for up to 1 year.


Clinical Trial Description

This study will include dose escalation and dose expansion phases.

In the dose escalation portion, patients with advanced cancer will be enrolled and treated with Durvalumab and Trabectedin. Durvalumab will be administered at the same dose in each dose escalation cohort, while the dose of Trabectedin will be progressively increased in different cohorts until the safest dose of the combination is determined.

In the dose expansion portion patients will be treated with the safest dose of the study drugs determined during the dose escalation phase. There will be two separate groups of patients treated at this dose to evaluate anti-tumor efficacy of the combination. One group will consist of non-small-cell lung cancer patients previously treated with PD-1 or PD-L1 inhibitors and another group will consist of an immunotherapy naive group of patients. This immunotherapy naive group of patients will include sarcoma and another tumor type, this other tumor type will be determined based on anti-tumor efficacy seen during the dose escalation.

The study drugs will be given intravenously every 3 weeks. Treatment will continue for up to one year or until disease progression. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03496519
Study type Interventional
Source University of Colorado, Denver
Contact Mark Morrow, Morrow
Phone 720-848-0665
Email mark.morrow@ucdenver.edu
Status Not yet recruiting
Phase Phase 1
Start date October 1, 2018
Completion date October 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03441100 - TCR-engineered T Cells in Solid Tumors Including NSCLC and HCC Patients Phase 1
Not yet recruiting NCT03638804 - 89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors N/A
Not yet recruiting NCT03600090 - EOC202 Plus First-line Paclitaxel Phase Ⅰ Trail in Chinese Patients With Metastatic Breast Cancer Phase 1
Recruiting NCT03209401 - Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies Phase 1
Recruiting NCT03355066 - A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03326479 - POA Retrospective Repository N/A
Recruiting NCT03017521 - K-BASKET, TAS-117, PI3K/AKT Gene Aberration Phase 2
Recruiting NCT02977364 - A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours Phase 1
Recruiting NCT03360734 - Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors Phase 1
Recruiting NCT03274661 - Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors Phase 2
Recruiting NCT03160833 - A Study of HMPL-453 in Patients With Advanced Solid Malignancies Phase 1/Phase 2
Active, not recruiting NCT03092934 - A Study of AK-01 (LY3295668) in Solid Tumors Phase 1/Phase 2
Recruiting NCT03520075 - Study of ASTX029 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03147378 - Food Effect Study of ModraDoc006 in Combination With Ritonavir Phase 1
Recruiting NCT03465592 - Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma Phase 1/Phase 2
Recruiting NCT03081819 - A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer Phase 1
Recruiting NCT03494231 - A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03004755 - The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
Recruiting NCT03545815 - Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. Phase 1
Not yet recruiting NCT03410121 - Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy N/A